Wuxi Biologics Cayman Inc

Wuxi Biologics (Cayman), Inc. is an investment holding company, which provides end-to-end solutions and services for biologics discovery, development, and manufacturing services and manufacturing of biologics products. It operates through the Biologics and XDC segments. The company was founded on February 27, 2014, and is headquartered in Wuxi, China.

Ranked in top 1% of the over 100,000 companies evaluated Recognized for outstanding performance across all areas: Environment, Labor & Human Rights, Ethics, and Sustainable Procurement Seen as a trusted partner by global clients for its strong sustainability commitment SHANGHAI , Dec. 8, 2023 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced it has been awarded the EcoVadis Sustainability Rating's Platinum Medal, the highest level of recognition granted to the companies being evaluated. EcoVadis is a leading ratings organization for the sustainability of supply chains.

WuXi Biologics Awarded Highest Platinum Medal by EcoVadis Sustainability Rating

WuXi Biologics is a contract-based drug developer in China, but recent share price performance has lagged. The company is expecting a major miss in revenues for FY 2023 due mostly to over-optimism, causing a 30% decline in share price. Despite the temporary issues, WuXi Biologics remains a great company with fast growth, profitability, and a solid financial foundation.

WuXi Biologics: Holiday Fire Sale For Leading CRDMO

By leveraging WuXiUPTM, WuXi Biologics has completed its first end-to-end continuous drug substance (DS) manufacturing from perfused cell culture to final UF/DF pool at pilot scale This end-to-end continuous bioprocess, which is in place for WuXi Biologics global manufacturing network, is currently being scaled up to GMP manufacturing   SHANGHAI , Nov. 22, 2023 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), announced today that it has accomplished end-to-end DS manufacturing at pilot scale utilizing WuXiUPTM, a proprietary ultra-high productivity continuous bioprocessing platform at its non-GMP pilot plant in Shanghai, China. Currently, this well configured bioprocess is being scaled up to GMP manufacturing and will be deployed across WuXi Biologics' global manufacturing sites in China, Ireland, U.S., Singapore.

WuXi Biologics Successfully Implemented a Fully Integrated Continuous Process with a Breakthrough Productivity of ~6 g/L/day at Pilot Scale

LONDON and SHANGHAI, China, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Myricx Bio (‘Myricx'), a UK biotech company focused on the discovery and development of a completely novel class of antibody-drug conjugate (ADC) payloads based on N-Myristoyltransferase inhibition (NMTi), and WuXi Biologics (“WuXi Bio”) (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), today announce that they have entered into a license agreement under which Myricx will have exclusive access to a proprietary antibody that was discovered based on WuXi Bio's integrated technology platforms.

Myricx Bio Enters into an Exclusive Antibody License Agreement with WuXi Biologics

SHANGHAI , Nov. 7, 2023 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced it has received an AAA rating from Morgan Stanley Capital International (MSCI) ESG Ratings, the highest rating for companies on MSCI's letter scale from AAA (Leaders) to CCC (Laggards). MSCI is a leading investment research firm that provides stock indexes and portfolio performance analytics to institutional investors.

WuXi Biologics Receives AAA MSCI ESG Rating

China-headquartered WuXi XDC, the contract medical researching unit of WuXi Biologics (Cayman) , said on Tuesday it intended to raise up to HK$3.68 billion ($470.56 million) in one of Hong Kong's top initial public offerings (IPO) this year.

WuXi Biologics' medical research unit eyes up to $471 mln in Hong Kong IPO

WuXiUI™ ultra-intensified fed-batch platform offers a new process option for maximum flexibility to meet various clients' needs in biologics development and manufacture. The platform can significantly improve productivity and quality, and reduce cost-of-goods (COGS) in commercial manufacturing The platform's unique design allows for outstanding adaptability for all common cell lines and diverse modalities WuXiUI™ showcases WuXi Biologics' efforts to incorporate sustainable and innovative concepts in its CRDMO services WUXI, China , Oct. 16, 2023 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced that it has launched a new proprietary bioprocessing platform WuXiUI™, an ultra-intensified, fed-batch solution that enhances the productivity and quality of multiple different CHO or other mammalian cell lines and product modalities.

WuXi Biologics Launches New High-Productivity Bioprocessing Platform WuXiUI™ for Cost-Effective Commercial Manufacturing and Desirable Product Quality

SAN RAFAEL, Calif.--(BUSINESS WIRE)--IMIDomics Inc., a patient-centric drug discovery and development company focused on Immune-Mediated Inflammatory Diseases (IMIDs), today announced that it has entered into an agreement with WuXi Biologics, a global Contract Research, Development and Manufacturing Organization, aimed at accelerating the development and manufacturing of IMIDomics IMB1001, a highly promising humanized antibody targeting CD226, a breakthrough target with the potential to treat I.

IMIDomics Announces Strategic Agreement with WuXi Biologics to Advance IMB1001 Antibody Development for Immune-Mediated Inflammatory Diseases

TAIPEI, Taiwan--(BUSINESS WIRE)--PharmaEssentia today announced it has entered into a license agreement with WuXi Biologics Ireland Limited.

PharmaEssentia Enters Into Exclusive Global License Agreement With WuXi Biologics for a Myeloid Immune Checkpoint Antibody Candidate

Gilead Sciences

abrdn Healthcare Investors 

iShares Nasdaq Biotechnology ETF

Illumina

IQVIA Hlds

Direxion Daily S&P Biotech Bull 3X Shares

Lonza Group AG

Merck

Navistar

Omega Healthcare Investors

Pfizer

Royalty Pharma

abrdn World Healthcare Fund 

SPDR S&P Biotech ETF

Health Care Select Sector SPDR Fund

The recent IRA list of 10 drug publications is not expected to have a significant impact on big pharma stocks in the near term. The legal challenges by big pharma companies against the IRA may derail the implementation of the drug pricing reforms. Investors can consider diversified biotech indexes or healthcare-focused ETFs for exposure to the biopharma sector.

Biopharma Bounce-Back: From Policy Pains To Profitable Plains

SHANGHAI , Aug. 10, 2023 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), and Boostimmune, a biotech company dedicated to developing next-generation anti-cancer therapies modulating the tumor immune microenvironment and ADCs to novel targets, announced a Memorandum of Understanding (MOU) had been signed for research and discovery services for Boostimmune's pipeline. Under the collaboration, Boostimmune will have access to WuXi Biologics' integrated discovery services and extensive expertise in antibody discovery, lead optimization, in vitro screening and characterization, as well as in vivo tests.

WuXi Biologics and Boostimmune Sign MOU for Exclusive Research and Discovery Services

SHANGHAI , June 26, 2023 /PRNewswire/ -- June 26 th, 2023, Pharmadule Morimatsu and WuXi Biologics officially entered into a global strategic cooperation for the Singapore CRDMO Center project of WuXi Biologics. As leaders in their respective fields, this strategic partnership marks an important milestone in both companies' business growth and development.

Pharmadule Morimatsu and WuXi Biologics Reached Global Strategic Partnership

DUBLIN--(BUSINESS WIRE)--IPS-Integrated Project Services, LLC, a leading provider of engineering, procurement, construction management, and validation (EPCMV) services, congratulates WuXi Biologics Ireland Limited (WuXi Biologics) for receiving a Facility of the Year Award (FOYA) from The International Society for Pharmaceutical Engineering (ISPE) in the Operations category for their Large-Scale Manufacturing Facility in Mullagharlin, Dundalk, Ireland. The IPS team of experts provided a range o.

WuXi Biologics Awarded an ISPE Facility of the Year Award in the Operations Category

DUNDALK, Ireland , May 22, 2023 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269. HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced that the International Society for Pharmaceutical Engineering (ISPE) has awarded the company a 2023 Facility of the Year Award (FOYA) in the Operations category.

WuXi Biologics Receives 2023 ISPE Facility of the Year Award for Operations

The Report outlines new goals of net-zero GHG emissions across all operations by 2050 and a 10% reduction of waste intensity by 2027 compared with 2022. The Company makes remarkable progress on environmental goals, achieving its water consumption intensity-reduction target in 2022, well ahead of the scheduled date of 2025.

WuXi Biologics Releases 2022 ESG Report Detailing Its Continued Commitment to Sustainability

WuXi Biologics ("WuXi Bio") (2269. HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO) and its subsidiary WuXi XDC congratulate their partner DualityBio, a clinical-stage biotech company focusing on the discovery and development of next generation ADC therapeutics for patients with cancer and autoimmune diseases, on entering into exclusive license and collaboration agreements with German based BioNTech, a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases, for two investigative antibody-drug conjugates ("ADC") therapeutics.

WuXi Biologics and WuXi XDC Congratulate DualityBio on Entering Global Licensing and Collaboration Agreements with BioNTech to Accelerate Development of Differentiated Antibody-Drug Conjugate Therapeutics

Revenue Increased b y 48.4% Y-o-Y to RMB15,268.7 Million Gross Profit Increased by 39.2% Y-o-Y to RMB6,724.0 Million Adjusted Net Profit Rose b y 47.1% to RMB5,053.9 Million Non-COVID Revenue Achieved 63% Y-o-Y Growth, Strong Momentum Continues into 2023 and Beyond " R" in CRDMO Business Model Accelerated to Extend Partnerships with Pharma Clients Positive Free Cash Flow to Support Sustainable Growth Total Backlog Surged to US$20,571 Million

WuXi Biologics Reports Remarkable 2022 Annual Results

SHANGHAI , Dec. 15, 2022 /PRNewswire/ -- WuXi Biologics ("WuXi Bio", 2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that its subsidiary WuXi Biologics (Shanghai) Co., Ltd. has been removed from the Unverified List (UVL) by the U.S. Department of Commerce, effective Dec. 16, 2022.

WuXi Biologics (Shanghai) Co., Ltd. Removed from the U.S. Commerce Department's Unverified List

SHANGHAI , Nov. 21, 2022 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), launched its Integrated Biologics CRDMO Center located in the district of Fengxian in Shanghai. The opening will add development and manufacturing capacity at the Center, with end-to-end services for diversified biologics to accelerate global clients' project timelines – from process development, analytical development, drug product development and quality control to pilot-scale manufacturing, clinical drug substance and drug product manufacturing.

WuXi Biologics Launches an Integrated Biologics CRDMO Center in Fengxian, Shanghai

SHANGHAI , Oct. 27, 2022 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269. HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), today updated its recent corporate progress.

WuXi Biologics Provides Corporate Updates

-  The 11th drug substance facility is released for cGMP operation in the WuXi Biologics' global manufacturing network. This new facility enhances the company's capability of providing commercial manufacturing at 4,000L to 20,000L scale, facilitating any project initiation within four weeks.

WuXi Biologics Announces GMP Release of 48,000L Commercial Drug Substance Manufacturing Facility in Hebei, China

WuXi Biologics adds further capacity and capability for drug product fill & finish, providing global customers with end-to-end integrated solutions for diversified modalities, including mRNA-LNP HANGZHOU, China , Oct. 23, 2022 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced its new drug product (DP) facility – named DP8 – located in Hangzhou, China, has completed the first batch of GMP manufacturing. The DP8 facility is the tenth operational drug product facility in WuXi Biologics' global network.

WuXi Biologics Released a New cGMP Drug Product Manufacturing Facility to Support End-to-End Services for Diversified Modalities

SHANGHAI , Oct. 13, 2022  /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that it has received the "Best CDMO Award of the Year" at the Asia-Pacific Biologics CMO Excellence Awards (APBCEA) 2022 hosted by IMAPAC. Over the years since 2017, WuXi Biologics has received multiple awards in various categories at IMAPAC's events.

WuXi Biologics Receives "Best CDMO Award of the Year"

SHANGHAI , Oct. 11, 2022 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), and Toregem BioPharma, a biotech startup company from Kyoto University, today announced that they have signed a Memorandum of Understanding (MOU) to form a strategic partnership in the development of TRG035, a monoclonal antibody targeting USAG-1 for the treatment of congenital adentia. Within the partnership, Toregem BioPharma will have access to WuXi Biologics' integrated CMC services in cell line development, cell banking and testing services, cell culture development, biologics GMP manufacturing, bioassay development, and related services.

WuXi Biologics and Toregem BioPharma Sign MOU for Development of Anti-USAG-1 Antibody

WUXI, China , Oct. 9, 2022 /PRNewswire/ -- WuXi Biologics ("WuXi Bio", 2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that its subsidiary WuXi Biologics Co., Ltd. located in Wuxi city was removed from the Unverified List (UVL) by the U.S. Department of Commerce, effective October 7, 2022.

News for Wuxi Biologics Cayman Inc Stock (WXXWY)